<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04442113</url>
  </required_header>
  <id_info>
    <org_study_id>ROC-STAR</org_study_id>
    <nct_id>NCT04442113</nct_id>
  </id_info>
  <brief_title>RandOmised Controlled Trial of STAR Mapping™ Guided Ablation for AF.</brief_title>
  <acronym>ROC-STAR</acronym>
  <official_title>Multicenter Randomized Controlled Trial Assessing Targeted Ablation in Persistent Atrial Fibrillation Using the Stochastic Trajectory Analysis of Ranked Signals (STAR Mapping™) Method.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm AI Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhythm AI Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence&#xD;
      over the next decade. Beyond causing troublesome symptoms AF is associated with increased&#xD;
      mortality and morbidity. Catheter ablation is a safe treatment which is effective for&#xD;
      paroxysmal AF but the success rate for persistent AF remains approximately 50% at 1 year. A&#xD;
      new mapping technique, called Stochastic Trajectory Analysis of Ranked signals (STAR&#xD;
      Mapping™) Method, has recently been developed. In a pilot study, localised sources driving AF&#xD;
      were consistently mapped and ablated with excellent acute and long term outcomes. This trial&#xD;
      will test the clinical effectiveness of this approach by comparing conventional ablation with&#xD;
      pulmonary vein isolation (PVI) to PVI plus STAR mapping™ guided ablation. We plan to test&#xD;
      this through a prospective multicenter randomized controlled trial including 177 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective multi-centre randomised controlled trial with two treatment arms.&#xD;
      We plan to include up to 15 UK centres. Patients that have been referred for catheter&#xD;
      ablation of symptomatic persistent AF will be recruited. Patients will be consented and have&#xD;
      their baseline review after having been listed for AF ablation on the hospital waiting list.&#xD;
      They will be randomized to one of two treatment arms. All patients will undergo their&#xD;
      procedure using a 3D mapping system. Standard catheters will be used during the ablation&#xD;
      procedure. Because the STAR mapping™ system will be configured for use with a special version&#xD;
      of the 3D mapping system Carto (BIosense Webster) the study will mandate use of clinically&#xD;
      approved Carto catheters: Smarttouch thermocool ablation catheter and the Pentarray mapping&#xD;
      catheter. Ablation procedures will be carried out using the usual policies and protocols of&#xD;
      the institutions involved except for the specific points below. The two treatment arms&#xD;
      include:&#xD;
&#xD;
        1. Control arm - PVI alone After PVI, no further ablation in AF will be allowed. If the&#xD;
           patient organizes into an atrial tachycardia (AT) during PVI this will be mapped and&#xD;
           ablated. Otherwise, in accordance with common clinical practice, a 30 minute waiting&#xD;
           period will be observed following PVI to watch for acute pulmonary vein reconnection.&#xD;
           During this waiting period, mapping data will be acquired using the multipolar pulmonary&#xD;
           vein mapping catheter to acquire STAR mapping™ data. The operator will be blinded to&#xD;
           these data. This is done using the pentarray mapping catheter to acquire a minimum of 10&#xD;
           widely spaced globally distributed left atrial recordings of 30 seconds each outside the&#xD;
           pulmonary veins. If the patient has remained in AF post PVI then electrical&#xD;
           cardioversion will be performed, the pulmonary veins checked and re-isolated if needed,&#xD;
           and the procedure terminated.&#xD;
&#xD;
        2. Experimental arm - PVI followed by STAR guided ablation. If the patient organises to&#xD;
           sinus rhythm after PVI alone then a 30 minute wait will be observed to ensure sustained&#xD;
           PVI and the procedure terminated. If patients remain in AF following PVI, the left&#xD;
           atrium will be mapped using a multipolar mapping catheter to acquire a minimum of 10&#xD;
           widely spaced globally distributed recordings outside the pulmonary veins. STAR mapping™&#xD;
           data will be exported and maps generated. Ablation will then be targeted at the leading&#xD;
           sites identified by STAR mapping™ in order of ranking (1st first, 2nd second, etc.) with&#xD;
           the end-point of AF termination. If AF terminates further sites will not be targeted. If&#xD;
           patients terminate to an atrial tachycardia then this will be mapped and ablated as per&#xD;
           standard clinical practice.&#xD;
&#xD;
      If AF persists following ablation of all STAR mapping™ identified sites then mapping of the&#xD;
      right atrium may be considered if the septum consistently activates early and the coronary&#xD;
      sinus activation is predominantly proximal to distal, and further ablation permitted in the&#xD;
      right atrium if indicated. If patients remain in AF following ablation then they will be&#xD;
      electrically cardioverted.&#xD;
&#xD;
      Follow-up All patients will undergo 12 months follow-up with an ECG at 3, 6, 9 and 12 months,&#xD;
      and a 48h ambulatory Holter monitor at 6 and 12 months. Patients will routinely continue&#xD;
      anti-arrhythmic therapy for up to 3 months post procedure which will be considered a blanking&#xD;
      period. After 3 months rhythmically active antiarrhythmic drugs will be stopped.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study cancelled. Different direction pursued by Rhythm AI.&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with clinical success</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical success is defined as freedom from atrial arrhythmia (AF or atrial tachycardia) lasting &gt;30 seconds after a single procedure off antiarrhythmic drugs subsequent to a 3 month blanking period (standard guideline definition of clinical success).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with termination of AF during ablation</measure>
    <time_frame>During the index procedure (i.e. day 0)</time_frame>
    <description>Termination of AF during ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with major complications following their index procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>major complications are defined as any complication causing death, disability, results in another intervention, or prolongs hospital stay (as per guidelines).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with early failure following their index procedure.</measure>
    <time_frame>3 months</time_frame>
    <description>Early failure is described as recurrent AF or atrial tachycardia at the 3 months time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups reaching a composite electrophysiological end point during their index procedure</measure>
    <time_frame>During the index ablation procedure (i.e. day 0)</time_frame>
    <description>The composite electrophysiological end point is comprised of either AF termination or slowing of AF cycle length ≥30ms measured from the left atrial appendage during ablation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency ablation time</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Duration of radiofrequency ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Duration of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with freedom from AF</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF defined as no documented AF (&gt;30 seconds) following the 3 months blanking period following a single procedure, off anti-arrhythmic drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with freedom from atrial arrhythmia allowing for antiarrhythmic drugs.</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from documented atrial arrhythmia (&gt;30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the proportion of subjects in the 2 groups with freedom from AF allowing for antiarrhythmic drugs</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AF defined as no documented AF (&gt;30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between the number of AF drivers identified using STAR mapping™ and clinical outcome</measure>
    <time_frame>12 months</time_frame>
    <description>The number of AF drivers identified will be correlated to the proportion of patients with clinical success at 1 year (the primary end-point). This analysis will be performed for all 177 patients, and for each of the 2 groups separately.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation alone (by catheter ablation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAR guided ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein isolation plus ablation guided by STAR MappingTM</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation plus ablation guided by novel STAR mapping™</intervention_name>
    <description>Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.</description>
    <arm_group_label>STAR guided ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent AF (continuous AF duration between 1 week and 24 months)&#xD;
&#xD;
          -  No previous AF ablation or other left atrial ablation&#xD;
&#xD;
          -  Undergoing a clinical AF ablation procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to sign consent&#xD;
&#xD;
          -  Any other contraindication to catheter ablation&#xD;
&#xD;
          -  Age &lt;18 years or &gt; 80 years&#xD;
&#xD;
          -  AF with a reversible cause&#xD;
&#xD;
          -  AF that is paroxysmal&#xD;
&#xD;
          -  AF that has been persistent &gt; 2 yrs&#xD;
&#xD;
          -  Previous left atrial ablation (percutaneous or surgical)&#xD;
&#xD;
          -  Severe LV impairment (EF &lt; 40%)&#xD;
&#xD;
          -  NYHA class 3 or 4 heart failure&#xD;
&#xD;
          -  Severely dilated left atrium (LA diameter &gt; 50 mm)&#xD;
&#xD;
          -  Known cardiomyopathy or inherited 'channelopathy'&#xD;
&#xD;
          -  Congential heart disease (excluding PFO)&#xD;
&#xD;
          -  More than moderate valvular heart disease or prosthetic heart valves&#xD;
&#xD;
          -  Prior MI, PCI or cardiac surgery in the last 6 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Morbid obesity (defined as BMI &gt;40)&#xD;
&#xD;
          -  Any other medical problem likely to cause death within the next 18 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>https://rhythm-ai.com/</url>
    <description>Rhythm AI Ltd website</description>
  </link>
  <reference>
    <citation>Honarbakhsh S, Hunter RJ, Finlay M, Ullah W, Keating E, Tinker A, Schilling RJ. Development, in vitro validation and human application of a novel method to identify arrhythmia mechanisms: The stochastic trajectory analysis of ranked signals mapping method. J Cardiovasc Electrophysiol. 2019 May;30(5):691-701. doi: 10.1111/jce.13882. Epub 2019 Mar 5.</citation>
    <PMID>30801836</PMID>
  </reference>
  <reference>
    <citation>Honarbakhsh S, Hunter RJ, Ullah W, Keating E, Finlay M, Schilling RJ. Ablation in Persistent Atrial Fibrillation Using Stochastic Trajectory Analysis of Ranked Signals (STAR) Mapping Method. JACC Clin Electrophysiol. 2019 Jul;5(7):817-829. doi: 10.1016/j.jacep.2019.04.007. Epub 2019 May 8.</citation>
    <PMID>31320010</PMID>
  </reference>
  <reference>
    <citation>Honarbakhsh S, Schilling RJ, Finlay M, Keating E, Ullah W, Hunter RJ. STAR mapping method to identify driving sites in persistent atrial fibrillation: Application through sequential mapping. J Cardiovasc Electrophysiol. 2019 Dec;30(12):2694-2703. doi: 10.1111/jce.14201. Epub 2019 Oct 3.</citation>
    <PMID>31552697</PMID>
  </reference>
  <reference>
    <citation>Honarbakhsh S, Schilling RJ, Keating E, Finlay M, Hunter RJ. Drivers in AF colocate to sites of electrogram organization and rapidity: Potential synergy between spectral analysis and STAR mapping approaches in prioritizing drivers for ablation. J Cardiovasc Electrophysiol. 2020 Jun;31(6):1340-1349. doi: 10.1111/jce.14456. Epub 2020 Apr 9.</citation>
    <PMID>32219906</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Cardiac mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04442113
org study id: ROC-STAR
nct id: NCT04442113
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence
      over the next decade. Beyond causing troublesome symptoms AF is associated with increased
      mortality and morbidity. Catheter ablation is a safe treatment which is effective for
      paroxysmal AF but the success rate for persistent AF remains approximately 50% at 1 year. A
      new mapping technique, called Stochastic Trajectory Analysis of Ranked signals (STAR
      Mapping™) Method, has recently been developed. In a pilot study, localised sources driving AF
      were consistently mapped and ablated with excellent acute and long term outcomes. This trial
      will test the clinical effectiveness of this approach by comparing conventional ablation with
      pulmonary vein isolation (PVI) to PVI plus STAR mapping™ guided ablation. We plan to test
      this through a prospective multicenter randomized controlled trial including 177 patients.
This will be a prospective multi-centre randomised controlled trial with two treatment arms.
      We plan to include up to 15 UK centres. Patients that have been referred for catheter
      ablation of symptomatic persistent AF will be recruited. Patients will be consented and have
      their baseline review after having been listed for AF ablation on the hospital waiting list.
      They will be randomized to one of two treatment arms. All patients will undergo their
      procedure using a 3D mapping system. Standard catheters will be used during the ablation
      procedure. Because the STAR mapping™ system will be configured for use with a special version
      of the 3D mapping system Carto (BIosense Webster) the study will mandate use of clinically
      approved Carto catheters: Smarttouch thermocool ablation catheter and the Pentarray mapping
      catheter. Ablation procedures will be carried out using the usual policies and protocols of
      the institutions involved except for the specific points below. The two treatment arms
      include:

        1. Control arm - PVI alone After PVI, no further ablation in AF will be allowed. If the
           patient organizes into an atrial tachycardia (AT) during PVI this will be mapped and
           ablated. Otherwise, in accordance with common clinical practice, a 30 minute waiting
           period will be observed following PVI to watch for acute pulmonary vein reconnection.
           During this waiting period, mapping data will be acquired using the multipolar pulmonary
           vein mapping catheter to acquire STAR mapping™ data. The operator will be blinded to
           these data. This is done using the pentarray mapping catheter to acquire a minimum of 10
           widely spaced globally distributed left atrial recordings of 30 seconds each outside the
           pulmonary veins. If the patient has remained in AF post PVI then electrical
           cardioversion will be performed, the pulmonary veins checked and re-isolated if needed,
           and the procedure terminated.

        2. Experimental arm - PVI followed by STAR guided ablation. If the patient organises to
           sinus rhythm after PVI alone then a 30 minute wait will be observed to ensure sustained
           PVI and the procedure terminated. If patients remain in AF following PVI, the left
           atrium will be mapped using a multipolar mapping catheter to acquire a minimum of 10
           widely spaced globally distributed recordings outside the pulmonary veins. STAR mapping™
           data will be exported and maps generated. Ablation will then be targeted at the leading
           sites identified by STAR mapping™ in order of ranking (1st first, 2nd second, etc.) with
           the end-point of AF termination. If AF terminates further sites will not be targeted. If
           patients terminate to an atrial tachycardia then this will be mapped and ablated as per
           standard clinical practice.

      If AF persists following ablation of all STAR mapping™ identified sites then mapping of the
      right atrium may be considered if the septum consistently activates early and the coronary
      sinus activation is predominantly proximal to distal, and further ablation permitted in the
      right atrium if indicated. If patients remain in AF following ablation then they will be
      electrically cardioverted.

      Follow-up All patients will undergo 12 months follow-up with an ECG at 3, 6, 9 and 12 months,
      and a 48h ambulatory Holter monitor at 6 and 12 months. Patients will routinely continue
      anti-arrhythmic therapy for up to 3 months post procedure which will be considered a blanking
      period. After 3 months rhythmically active antiarrhythmic drugs will be stopped.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Randomised controlled trial
primary purpose: Treatment
masking: None (Open Label)
measure: Comparison of the proportion of subjects in the 2 groups with clinical success
time frame: 12 months
description: Clinical success is defined as freedom from atrial arrhythmia (AF or atrial tachycardia) lasting >30 seconds after a single procedure off antiarrhythmic drugs subsequent to a 3 month blanking period (standard guideline definition of clinical success).
measure: Comparison of the proportion of subjects in the 2 groups with termination of AF during ablation
time frame: During the index procedure (i.e. day 0)
description: Termination of AF during ablation
measure: Comparison of the proportion of subjects in the 2 groups with major complications following their index procedure.
time frame: 30 days
description: major complications are defined as any complication causing death, disability, results in another intervention, or prolongs hospital stay (as per guidelines).
measure: Comparison of the proportion of subjects in the 2 groups with early failure following their index procedure.
time frame: 3 months
description: Early failure is described as recurrent AF or atrial tachycardia at the 3 months time point.
measure: Comparison of the proportion of subjects in the 2 groups reaching a composite electrophysiological end point during their index procedure
time frame: During the index ablation procedure (i.e. day 0)
description: The composite electrophysiological end point is comprised of either AF termination or slowing of AF cycle length ≥30ms measured from the left atrial appendage during ablation.
measure: Radiofrequency ablation time
time frame: Intraprocedural
description: Duration of radiofrequency ablation
measure: Procedure time
time frame: Intraprocedural
description: Duration of procedure
measure: Comparison of the proportion of subjects in the 2 groups with freedom from AF
time frame: 12 months
description: Freedom from AF defined as no documented AF (>30 seconds) following the 3 months blanking period following a single procedure, off anti-arrhythmic drugs.
measure: Comparison of the proportion of subjects in the 2 groups with freedom from atrial arrhythmia allowing for antiarrhythmic drugs.
time frame: 12 months
description: Freedom from documented atrial arrhythmia (>30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.
measure: Comparison of the proportion of subjects in the 2 groups with freedom from AF allowing for antiarrhythmic drugs
time frame: 12 months
description: Freedom from AF defined as no documented AF (>30 seconds) following the 3 months blanking period following a single procedure, allowing for anti-arrhythmic drugs.
measure: Relationship between the number of AF drivers identified using STAR mapping™ and clinical outcome
time frame: 12 months
description: The number of AF drivers identified will be correlated to the proportion of patients with clinical success at 1 year (the primary end-point). This analysis will be performed for all 177 patients, and for each of the 2 groups separately.
arm group label: Control group
arm group type: Active Comparator
description: Pulmonary vein isolation alone (by catheter ablation)
arm group label: STAR guided ablation group
arm group type: Experimental
description: Pulmonary vein isolation plus ablation guided by STAR MappingTM
intervention type: Procedure
intervention name: Pulmonary vein isolation plus ablation guided by novel STAR mapping™
description: Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
arm group label: STAR guided ablation group
intervention type: Procedure
intervention name: Pulmonary vein isolation
description: Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
arm group label: Control group
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
url: https://rhythm-ai.com/
description: Rhythm AI Ltd website
citation: Honarbakhsh S, Hunter RJ, Finlay M, Ullah W, Keating E, Tinker A, Schilling RJ. Development, in vitro validation and human application of a novel method to identify arrhythmia mechanisms: The stochastic trajectory analysis of ranked signals mapping method. J Cardiovasc Electrophysiol. 2019 May;30(5):691-701. doi: 10.1111/jce.13882. Epub 2019 Mar 5.
PMID: 30801836
citation: Honarbakhsh S, Hunter RJ, Ullah W, Keating E, Finlay M, Schilling RJ. Ablation in Persistent Atrial Fibrillation Using Stochastic Trajectory Analysis of Ranked Signals (STAR) Mapping Method. JACC Clin Electrophysiol. 2019 Jul;5(7):817-829. doi: 10.1016/j.jacep.2019.04.007. Epub 2019 May 8.
PMID: 31320010
citation: Honarbakhsh S, Schilling RJ, Finlay M, Keating E, Ullah W, Hunter RJ. STAR mapping method to identify driving sites in persistent atrial fibrillation: Application through sequential mapping. J Cardiovasc Electrophysiol. 2019 Dec;30(12):2694-2703. doi: 10.1111/jce.14201. Epub 2019 Oct 3.
PMID: 31552697
citation: Honarbakhsh S, Schilling RJ, Keating E, Finlay M, Hunter RJ. Drivers in AF colocate to sites of electrogram organization and rapidity: Potential synergy between spectral analysis and STAR mapping approaches in prioritizing drivers for ablation. J Cardiovasc Electrophysiol. 2020 Jun;31(6):1340-1349. doi: 10.1111/jce.14456. Epub 2020 Apr 9.
PMID: 32219906
responsible party type: Sponsor
mesh term: Atrial Fibrillation